This booklet is for men who are having hormone therapy for prostate cancer, their partners and families. It describes the different types of hormone therapy, how they work and what the treatment involves. It includes information on the possible side effects men may experience and suggests ways to help manage these.

Last updated: June 2019
To be reviewed: December 2021

References  

  • Kumar S, Shelley M, Harrison C, Coles B, Wilt T, Mason M. Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer (review). Cochrane Database Syst Rev. 2006;(4).
  • Shelley MD, Kumar S, Wilt T, Staffurth J, Coles B, Mason MD. A systematic review and meta-analysis of randomised trials of neo-adjuvant hormone therapy for localised and locally advanced prostate carcinoma. Cancer Treat Rev. 2009 Feb;35(1):9–17.
  • National Institute for Health and Care Excellence. Prostate Cancer: diagnosis and treatment. Full guideline 175. 2014.
  • Mottet N, Van den Bergh RCN, Briers E, Bourke L, Cornford P, De Santis M, et al. EAU - ESTRO - ESUR - SIOG Guidelines on Prostate Cancer. European Association of Urology; 2018.
  • Schmidt-Hansen M, Hoskin P, Kirkbride P, Hasler E, Bromham N. Hormone and Radiotherapy versus Hormone or Radiotherapy Alone for Non-metastatic Prostate Cancer: A Systematic Review with Meta-analyses. Clin Oncol. 2014 Oct;26(10):e21–46.
  • Crouzet S, Chapelon JY, Rouvière O, Mege-Lechevallier F, Colombel M, Tonoli-Catez H, et al. Whole-gland Ablation of Localized Prostate Cancer with High-intensity Focused Ultrasound: Oncologic Outcomes and Morbidity in 1002 Patients. Eur Urol [Internet]. [cited 2013 May 28]; Available from: http://www.sciencedirect.com/science/article/pii/S0302283813004247
  • Bekelman JE, Mitra N, Handorf EA, Uzzo RG, Hahn SA, Polsky D, et al. Effectiveness of androgen-deprivation therapy and radiotherapy for older men with locally advanced prostate cancer. J Clin Oncol Off J Am Soc Clin Oncol. 2015 Mar 1;33(7):716–22.
  • Mason MD, Parulekar WR, Sydes MR, Brundage M, Kirkbride P, Gospodarowicz M, et al. Final Report of the Intergroup Randomized Study of Combined Androgen-Deprivation Therapy Plus Radiotherapy Versus Androgen-Deprivation Therapy Alone in Locally Advanced Prostate Cancer. J Clin Oncol [Internet]. 2015 Feb 17 [cited 2015 May 8]; Available from: http://jco.ascopubs.org/cgi/doi/10.1200/JCO.2014.57.7510
  • Artibani W, Porcaro AB, De Marco V, Cerruto MA, Siracusano S. Management of Biochemical Recurrence after Primary Curative Treatment for Prostate Cancer: A Review. Urol Int. 2018;100(3):251–62.
  • Schröder F, Crawford ED, Axcrona K, Payne H, Keane TE. Androgen deprivation therapy: past, present and future. BJU Int. 2012 Jun;109 Suppl 6:1–12.
  • National Institute for Health and Care Excellence. Degarelix for treating advanced hormone-dependent prostate cancer. Technology appraisal guidance 404 [Internet]. 2016. Available from: https://www.nice.org.uk/guidance/TA404/chapter/1-Recommendations
  • Fang C, Wu C-L, Liu S-S, Ge L, Bai J-L. Efficacy, safety, and dose comparison of degarelix for the treatment of prostate cancer: A systematic review and meta-analysis. World J Meta-Anal. 2016 Jun 26;4(3):69–76.
  • Visapää H. Switching from an LHRH Antagonist to an LHRH Agonist: A Case Report of 10 Finnish Patients with Advanced Prostate Cancer. Oncol Ther. 2017;5(1):119–23.
  • Asakawa J, Iguchi T, Tamada S, Yasuda S, Ninomiya N, Kato M, et al. A change from gonadotropin releasing hormone antagonist to gonadotropin releasing hormone agonist therapy does not affect the oncological outcomes in hormone sensitive prostate cancer. Basic Clin Androl [Internet]. 2018 Jul 18 [cited 2019 Jun 17];28. Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050721/
  • Sharifi N, Gulley JL, Dahut WL. An Update on Androgen Deprivation Therapy for Prostate Cancer. Endocr Relat Cancer. 2010 Dec;17(4):R305–15.
  • Shore ND. Experience with degarelix in the treatment of prostate cancer. Ther Adv Urol. 2012;1756287212461048.
  • Klotz L, Boccon-Gibod L, Shore ND, Andreou C, Persson B-E, Cantor P, et al. The efficacy and safety of degarelix: a 12-month, comparative, randomized, open-label, parallel-group phase III study in patients with prostate cancer. BJU Int. 2008 Dec;102(11):1531–8.
  • Shore ND, Abrahamsson P-A, Anderson J, Crawford ED, Lange P. New considerations for ADT in advanced prostate cancer and the emerging role of GnRH antagonists. Prostate Cancer Prostatic Dis. 2013;16(1):7–15.
  • Nguyen PL, Alibhai SMH, Basaria S, D’Amico AV, Kantoff PW, Keating NL, et al. Adverse Effects of Androgen Deprivation Therapy and Strategies to Mitigate Them. Eur Urol. 2015 May;67(5):825–36.
  • Kunath F, Grobe HR, Rücker G, Motschall E, Antes G, Dahm P, et al. Non-steroidal antiandrogen monotherapy compared with luteinising hormone-releasing hormone agonists or surgical castration monotherapy for advanced prostate cancer (review). Cochrane Database Syst Rev. 2014;(6).
  • Electronic Medicines Compendium. Bicalutamide 150 mg film-coated tablets. - Patient Information Leaflet [Internet]. 2018 [cited 2019 May 20]. Available from: https://www.medicines.org.uk/emc/product/9687/pil
  • Electronic Medicines Compendium. Cyprostat 100mg - Patient Information Leaflet [Internet]. 2017 [cited 2019 May 20]. Available from: https://www.medicines.org.uk/emc/product/6249/pil
  • Electronic Medicines Compendium. Flutamide 250 mg Tablets - Patient Information Leaflet [Internet]. 2016 [cited 2019 May 20]. Available from: https://www.medicines.org.uk/emc/product/8428/pil
  • National Institute for Health and Care Excellence. Abiraterone for treating metastatic hormone-relapsed prostate cancer before chemotherapy is indicated. Technology appraisal guidance 387. 2016.
  • Scher HI, Fizazi K, Saad F, Taplin M-E, Sternberg CN, Miller K, et al. Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med. 2012 Sep 27;367(13):1187–97.
  • Galletti G, Leach BI, Lam L, Tagawa ST. Mechanisms of resistance to systemic therapy in metastatic castration-resistant prostate cancer. Cancer Treat Rev. 2017 Jun;57:16–27.
  • Beer TM, Armstrong AJ, Rathkopf D, Loriot Y, Sternberg CN, Higano CS, et al. Enzalutamide in Men with Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer: Extended Analysis of the Phase 3 PREVAIL Study. Eur Urol. 2017 Feb;71(2):151–4.
  • Litwin MS, Tan H-J. The Diagnosis and Treatment of Prostate Cancer: A Review. JAMA. 2017 Jun 27;317(24):2532.
  • Ritch CR, Cookson MS. Advances in the management of castration resistant prostate cancer. BMJ. 2016 Oct 17;i4405.
  • Loriot Y, Miller K, Sternberg CN, Fizazi K, De Bono JS, Chowdhury S, et al. Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial. Lancet Oncol. 2015;16(5):509–521.
  • Cella D, Ivanescu C, Holmstrom S, Bui CN, Spalding J, Fizazi K. Impact of enzalutamide on quality of life in men with metastatic castration-resistant prostate cancer after chemotherapy: additional analyses from the AFFIRM randomized clinical trial. Ann Oncol. 2015 Jan;26(1):179–85.
  • Bosset P-O, Albiges L, Seisen T, de la Motte Rouge T, Phé V, Bitker M-O, et al. Current role of diethylstilbestrol in the management of advanced prostate cancer. BJU Int. 2012 Dec;110(11c):E826–9.
  • Grenader T, Plotkin Y, Gips M, Cherny N, Gabizon A. Diethylstilbestrol for the treatment of patients with castration-resistant prostate cancer: Retrospective analysis of a single institution experience. Oncol Rep. 2014 Jan 1;31(1):428–34.
  • Turo R, Smolski M, Esler R, Kujawa ML, Bromage SJ, Oakley N, et al. Diethylstilboestrol for the treatment of prostate cancer: past, present and future. Scand J Urol. 2014 Feb;48(1):4–14.
  • Wilkins A, Shahidi M, Parker C, Gunapala R, Thomas K, Huddart R, et al. Diethylstilbestrol in castration-resistant prostate cancer. BJU Int. 2012 Dec 1;110(11b):E727–35.
  • Ndibe C, Wang CG, Sonpavde G. Corticosteroids in the Management of Prostate Cancer: A Critical Review. Curr Treat Options Oncol. 2015;16(2).
  • Dorff TB, Crawford ED. Management and challenges of corticosteroid therapy in men with metastatic castrate-resistant prostate cancer. Ann Oncol. 2013 Jan 1;24(1):31–8.
  • Louda MA, Valis M, Splichalova J, Pacovský J, Khaled B, Podhola M, et al. Psychosocial implications and the duality of life outcomes for patients with prostate carcinoma after bilateral orchiectomy. [Internet]. undefined. 2012 [cited 2018 Sep 7]. Available from: /paper/Psychosocial-implications-and-the-duality-of-life-Louda-Valis/b8c4e31ac3199a32336e7f61a6687bf49cc29c10
  • Eziefula CU, Grunfeld EA, Hunter MS. ‘You know I’ve joined your club… I’m the hot flush boy’: a qualitative exploration of hot flushes and night sweats in men undergoing androgen deprivation therapy for prostate cancer. Psychooncology. 2013 Dec;22(12):2823–30.
  • Irani J, Salomon L, Oba R, Bouchard P, Mottet N. Efficacy of venlafaxine, medroxyprogesterone acetate, and cyproterone acetate for the treatment of vasomotor hot flushes in men taking gonadotropin-releasing hormone analogues for prostate cancer: a double-blind, randomised trial. Lancet Oncol. 2010 Feb;11(2):147–54.
  • Karling P, Hammar M, Varenhorst E. Prevalence and duration of hot flushes after surgical or medical castration in men with prostatic carcinoma. J Urol. 1994 Oct;152(4):1170–3.
  • Tombal B. A Holistic Approach to Androgen Deprivation Therapy: Treating the Cancer without Hurting the Patient. Urol Int. 2009;83(4):373–8.
  • Iversen P, Karup C, Van der Meulen E, Tanko LB, Huhtaniemi I. Hot flushes in prostatic cancer patients during androgen-deprivation therapy with monthly dose of degarelix or leuprolide. Prostate Cancer Prostatic Dis. 2011;14(2):184–190.
  • Rhee H, Gunter JH, Heathcote P, Ho K, Stricker P, Corcoran NM, et al. Adverse effects of androgen-deprivation therapy in prostate cancer and their management. BJU Int. 2014;115(S5):3–13.
  • Jones JM, Kohli M, Loprinzi CL. Androgen deprivation therapy-associated vasomotor symptoms. Asian J Androl. 2012 Jan 30;14(2):193–7.
  • Ahmadi H, Daneshmand S. Androgen deprivation therapy: evidence-based management of side effects. BJU Int. 2013 Apr;111(4):543–8.
  • Drewe J, Bucher KA, Zahner C. A systematic review of non-hormonal treatments of vasomotor symptoms in climacteric and cancer patients. SpringerPlus [Internet]. 2015 [cited 2018 Nov 23];4(1). Available from: http://www.springerplus.com/content/4/1/65
  • Lee MS, Kim K-H, Shin B-C, Choi S-M, Ernst E. Acupuncture for treating hot flushes in men with prostate cancer: a systematic review. Support Care Cancer. 2009 Feb 18;17(7):763–70.
  • Elkins GR, Kendrick C, Koep L. Hypnotic Relaxation Therapy for Treatment of Hot Flashes Following Prostate Cancer Surgery: A Case Study. Int J Clin Exp Hypn. 2014 Jul 3;62(3):251–9.
  • Stefanopoulou E, Yousaf O, Grunfeld EA, Hunter MS. A randomised controlled trial of a brief cognitive behavioural intervention for men who have hot flushes following prostate cancer treatment (MANCAN). Psychooncology. 2015 Sep;24(9):1159–66.
  • Teschke R, Schwarzenboeck A, Schmidt-Taenzer W, Wolff A, Hennermann K-H. Herb induced liver injury presumably caused by black cohosh: A survey of initially purported cases and herbal quality specifications. 2011;11.
  • Tavakoli J, Miar S, Majid Zadehzare M, Akbari H. Evaluation of Effectiveness of Herbal Medication in Cancer Care: A Review Study. Iran J Cancer Prev. 2012;5(3):144–56.
  • Langston B, Armes J, Levy A, Tidey E, Ream E. The prevalence and severity of fatigue in men with prostate cancer: a systematic review of the literature. Support Care Cancer Off J Multinatl Assoc Support Care Cancer. 2013 Jun;21(6):1761–71.
  • Gardner JR, Livingston PM, Fraser SF. Effects of Exercise on Treatment-Related Adverse Effects for Patients With Prostate Cancer Receiving Androgen-Deprivation Therapy: A Systematic Review. J Clin Oncol. 2014 Feb 1;32(4):335–46.
  • Mottet N, Prayer-Galetti T, Hammerer P, Kattan MW, Tunn U. Optimizing outcomes and quality of life in the hormonal treatment of prostate cancer. BJU Int. 2006 Jul;98(1):20–7.
  • Haliloglu A, Baltaci S, Yaman O. Penile length changes in men treated with androgen suppression plus radiation therapy for local or locally advanced prostate cancer. J Urol. 2007 Jan;177(1):128–30.
  • Park KK, Lee SH, Chung BH. The Effects of Long‐Term Androgen Deprivation Therapy on Penile Length in Patients with Prostate Cancer: A Single‐Center, Prospective, Open‐Label, Observational Study. J Sex Med. 2011 Nov;8(11):3214–9.
  • Hwang TI-S, Lin Y-C, Lee MC-C, Juang G-D, Yeh C-H, Cheng Y-H, et al. The Effects of Medical Castration on Testes in Patients With Advanced Prostate Cancer. Urol Sci. 2010 Dec;21(4):169–74.
  • Elliott S, Latini DM, Walker LM, Wassersug R, Robinson JW. Androgen Deprivation Therapy for Prostate Cancer: Recommendations to Improve Patient and Partner Quality of Life: Improving Life on ADT. J Sex Med. 2010 Sep;7(9):2996–3010.
  • Kadono Y, Nohara T, Kawaguchi S, Sakamoto J, Makino T, Nakashima K, et al. Changes in penile length after radical prostatectomy: effect of neoadjuvant androgen deprivation therapy. Andrology [Internet]. 2018 Jul 2 [cited 2018 Nov 26]; Available from: http://doi.wiley.com/10.1111/andr.12517
  • Prostate Cancer UK and Stonewall. Exploring the needs of gay and bisexual men dealing with prostate cancer. 2013.
  • Haseen F, Murray LJ, Cardwell CR, O’Sullivan JM, Cantwell MM. The effect of androgen deprivation therapy on body composition in men with prostate cancer: Systematic review and meta-analysis. J Cancer Surviv. 2010 Jun 1;4(2):128–39.
  • Owen PJ, Daly RM, Livingston PM, Fraser SF. Lifestyle guidelines for managing adverse effects on bone health and body composition in men treated with androgen deprivation therapy for prostate cancer: an update. Prostate Cancer Prostatic Dis. 2017 Jun;20(2):137–45.
  • Keogh JWL, MacLeod RD. Body Composition, Physical Fitness, Functional Performance, Quality of Life, and Fatigue Benefits of Exercise for Prostate Cancer Patients: A Systematic Review. J Pain Symptom Manage. 2012 Jan;43(1):96–110.
  • Treanor CJ, Li J, Donnelly M. Cognitive impairment among prostate cancer patients: An overview of reviews. Eur J Cancer Care (Engl). 2017 Nov 1;26(6):e12642.
  • Wu LM, Tanenbaum ML, Dijkers MPJM, Amidi A, Hall SJ, Penedo FJ, et al. Cognitive and neurobehavioral symptoms in patients with non-metastatic prostate cancer treated with androgen deprivation therapy or observation: A mixed methods study. Soc Sci Med. 2016 May 1;156:80–9.
  • Gunlusoy B, Ceylan Y, Koskderelioglu A, Gedizlioglu M, Degirmenci T, Ortan P, et al. Cognitive Effects of Androgen Deprivation Therapy in Men With Advanced Prostate Cancer. Urology. 2017 May 1;103:167–72.
  • Nead KT, Sinha S, Nguyen PL. Androgen deprivation therapy for prostate cancer and dementia risk: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2017 Sep;20(3):259–64.
  • Sun M, Cole AP, Hanna N, Mucci LA, Berry DL, Basaria S, et al. Cognitive Impairment in Men with Prostate Cancer Treated with Androgen Deprivation Therapy: A Systematic Review and Meta-Analysis. J Urol. 2018 Jun 1;199(6):1417–25.
  • Marzouk S, Naglie G, Tomlinson G, Duff Canning S, Breunis H, Timilshina N, et al. Impact of Androgen Deprivation Therapy on Self-Reported Cognitive Function in Men with Prostate Cancer. J Urol [Internet]. 2018 Mar 1 [cited 2018 Aug 10]; Available from: http://www.sciencedirect.com/science/article/pii/S0022534718393790
  • Fagerlund A, Cormio L, Palangi L, Lewin R, Santanelli di Pompeo F, Elander A, et al. Gynecomastia in Patients with Prostate Cancer: A Systematic Review. PLoS ONE [Internet]. 2015 Aug 26 [cited 2018 Sep 12];10(8). Available from: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4550398/
  • Di Lorenzo G, Autorino R, Perdonà S, De Placido S. Management of gynaecomastia in patients with prostate cancer: a systematic review. Lancet Oncol. 2005 Dec 1;6(12):972–9.
  • Murad MH, Johnson, Kermott. Gynecomastia - evaluation and current treatment options. Ther Clin Risk Manag. 2011 Mar;145.
  • Higano CS. Side effects of androgen deprivation therapy: monitoring and minimizing toxicity. Urology. 2003;61(2):32–38.
  • Viani GA, Bernardes da Silva LG, Stefano EJ. Prevention of Gynecomastia and Breast Pain Caused by Androgen Deprivation Therapy in Prostate Cancer: Tamoxifen or Radiotherapy? Int J Radiat Oncol. 2012 Jul 15;83(4):e519–24.
  • Fradet Y, Egerdie B, Andersen M, Tammela TLJ, Nachabe M, Armstrong J, et al. Tamoxifen as Prophylaxis for Prevention of Gynaecomastia and Breast Pain Associated with Bicalutamide 150 mg Monotherapy in Patients with Prostate Cancer: A Randomised, Placebo-Controlled, Dose–Response Study. Eur Urol. 2007 Jul 1;52(1):106–15.
  • Wibowo E, Pollock PA, Hollis N, Wassersug RJ. Tamoxifen in men: a review of adverse events. Andrology. 2016;4(5):776–88.
  • Casey RG, Corcoran NM, Larry Goldenberg S. Quality of life issues in men undergoing androgen deprivation therapy: a review. Asian J Androl. 2012 Mar;14(2):226–31.
  • Alibhai SMH, Gogov S, Allibhai Z. Long-term side effects of androgen deprivation therapy in men with non-metastatic prostate cancer: A systematic literature review. Crit Rev Oncol Hematol. 2006 Dec;60(3):201–15.
  • Serpa Neto A, Tobias-Machado M, Esteves MAP, Senra MD, Wroclawski ML, Fonseca FLA, et al. Bisphosphonate therapy in patients under androgen deprivation therapy for prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2012;15(1):36–44.
  • National Institute for Health and Clinical Excellence. Osteoporosis: assessing the risk of fragility fracture. Short clinical guideline. Clinical guideline 146 [Internet]. 2012 [cited 2015 Nov 16]. Available from: https://www.nice.org.uk/guidance/cg146/evidence/osteoporosis-fragility-fracture-full-guideline-186818365
  • Abrahamsen B, Brask-Lindemann D, Rubin KH, Schwarz P. A review of lifestyle, smoking and other modifiable risk factors for osteoporotic fractures. BoneKEy Rep. 2014 Sep 3;3:574.
  • NHS Choices. Alcohol units [Internet]. nhs.uk. 2018 [cited 2018 Sep 10]. Available from: https://www.nhs.uk/live-well/alcohol-support/calculating-alcohol-units/
  • Todenhöfer T, Stenzl A, Hofbauer LC, Rachner TD. Targeting Bone Metabolism in Patients with Advanced Prostate Cancer: Current Options and Controversies. Int J Endocrinol. 2015;2015:1–9.
  • Cormie P, Galvão DA, Spry N, Joseph D, Chee R, Taaffe DR, et al. Can supervised exercise prevent treatment toxicity in patients with prostate cancer initiating androgen-deprivation therapy: a randomised controlled trial. BJU Int. 2015;115(2):256–66.
  • Thorsen L, Courneya KS, Stevinson C, Fosså SD. A systematic review of physical activity in prostate cancer survivors: outcomes, prevalence, and determinants. Support Care Cancer. 2008 Feb 15;16(9):987–97.
  • Keilani M, Hasenoehrl T, Baumann L, Ristl R, Schwarz M, Marhold M, et al. Effects of resistance exercise in prostate cancer patients: a meta-analysis. Support Care Cancer. 2017 Jun 10;
  • Mohile SG, Mustian K, Bylow K, Hall W, Dale W. Management of complications of androgen deprivation therapy in the older man. Crit Rev Oncol Hematol. 2009 Jun;70(3):235–55.
  • Baumann FT, Zopf EM, Bloch W. Clinical exercise interventions in prostate cancer patients: a systematic review of randomized controlled trials. Support Care Cancer. 2012;20(2):221–33.
  • Poole KES, Compston JE. Osteoporosis and its management. BMJ. 2006 Dec 16;333(7581):1251–6.
  • Macherey S, Monsef I, Jahn F, Jordan K, Yuen KK, Heidenreich A, et al. Bisphosphonates for advanced prostate cancer. Cochrane Database Syst Rev [Internet]. 2017 Dec 26 [cited 2018 Jan 5]; Available from: http://onlinelibrary.wiley.com/doi/10.1002/14651858.CD006250.pub2/abstract
  • Smith MR, Egerdie B, Toriz NH, Feldman R, Tammela TLJ, Saad F, et al. Denosumab in Men Receiving Androgen-Deprivation Therapy for Prostate Cancer. N Engl J Med. 2009 Aug 20;361(8):745–55.
  • National Institute for Health and Care Excellence. Prostate cancer: diagnosis and management. NICE clinical guideline 175 [Internet]. 2014 [cited 2013 Apr 25]. Available from: http://www.nice.org.uk/guidance/CG175
  • Healthcare Improvement Scotland. Denosumab for the prevention of skeletal-related events in adults with bone metastases from solid tumours. NICE (Multiple) Technology Appraisal Guidance No 265 [Internet]. [cited 2015 May 13]. Available from: http://www.healthcareimprovementscotland.org/programmes/nice_guidance_and_scotland/mta_resources/appraisal_265.aspx?iru=FV15K62K54
  • Azoulay L, Yin H, Benayoun S, Renoux C, Boivin J-F, Suissa S. Androgen-Deprivation Therapy and the Risk of Stroke in Patients With Prostate Cancer. Eur Urol. 2011 Dec;60(6):1244–50.
  • Crawley D, Garmo H, Rudman S, Stattin P, Häggström C, Zethelius B, et al. Association between duration and type of androgen deprivation therapy and risk of diabetes in men with prostate cancer. Int J Cancer. 2016;139(12):2698–704.
  • Jhan J-H, Yeh H-C, Chang Y-H, Guu S-J, Wu W-J, Chou Y-H, et al. New-onset diabetes after androgen-deprivation therapy for prostate cancer: A nationwide propensity score-matched four-year longitudinal cohort study. J Diabetes Complications. 2018 Jul;32(7):688–92.
  • Guo Z, Huang Y, Gong L, Gan S, Chan FL, Gu C, et al. Association of androgen deprivation therapy with thromboembolic events in patients with prostate cancer: a systematic review and meta-analysis. Prostate Cancer Prostatic Dis. 2018 Jul 9;1.
  • Nead KT, Boldbaatar N, Yang DD, Sinha S, Nguyen PL. Association of Androgen Deprivation Therapy and Thromboembolic Events: a Systematic Review and Meta-Analysis. Urology [Internet]. 2018 Jan [cited 2018 Jan 29]; Available from: http://linkinghub.elsevier.com/retrieve/pii/S0090429518300165
  • Hicks BM, Klil-Drori AJ, Yin H, Campeau L, Azoulay L. Androgen Deprivation Therapy and the Risk of Anemia in Men with Prostate Cancer: Epidemiology. 2017 Sep;28(5):712–8.
  • Saylor PJ, Smith MR. Metabolic Complications of Androgen Deprivation Therapy for Prostate Cancer. J Urol. 2013 Jan;189(1):S34–44.
  • Nguyen PL, Je Y, Schutz FAB, Hoffman KE, Hu JC, Parekh A, et al. Association of Androgen Deprivation Therapy With Cardiovascular Death in Patients With Prostate Cancer: A Meta-analysis of Randomized Trials. JAMA. 2011 Dec 7;306(21):2359–66.
  • Sharpley CF, Christie DRH, Bitsika V. Do hormone treatments for prostate cancer cause anxiety and depression? Int J Clin Oncol. 2014;19(3):523–30.
  • Nead KT, Sinha S, Yang DD, Nguyen PL. Association of androgen deprivation therapy and depression in the treatment of prostate cancer: A systematic review and meta-analysis. Urol Oncol Semin Orig Investig. 2017 Nov 1;35(11):664.e1-664.e9.
  • Gagliano-Jucá T, Travison TG, Nguyen PL, Kantoff PW, Taplin M-E, Kibel AS, et al. Effects of Androgen Deprivation Therapy on Pain Perception, Quality of Life, and Depression in Men With Prostate Cancer. J Pain Symptom Manage. 2018 Feb 1;55(2):307-317.e1.
  • Beck AM, Robinson JW, Carlson LE. Sexual intimacy in heterosexual couples after prostate cancer treatment: What we know and what we still need to learn. Urol Oncol Semin Orig Investig. 2009 Mar;27(2):137–43.
  • Oliffe J. Embodied masculinity and androgen deprivation therapy. Sociol Health Illn. 2006 May;28(4):410–32.
  • Foley E, Baillie A, Huxter M, Price M, Sinclair E. Mindfulness-based cognitive therapy for individuals whose lives have been affected by cancer: A randomized controlled trial. J Consult Clin Psychol. 2010 Feb;78(1):72–9.
  • Chaoul A, Milbury K, Sood AK, Prinsloo S, Cohen L. Mind-Body Practices in Cancer Care. Curr Oncol Rep. 2014 Dec;16(12):417.
  • Zhang M-F, Wen Y-S, Liu W-Y, Peng L-F, Wu X-D, Liu Q-W. Effectiveness of Mindfulness-based Therapy for Reducing Anxiety and Depression in Patients With Cancer: A Meta-analysis. Medicine (Baltimore). 2015 Nov;94(45):e0897-0890.
  • Dong Z, Wang H, Xu M, Li Y, Hou M, Wei Y, et al. Intermittent hormone therapy versus continuous hormone therapy for locally advanced prostate cancer: a meta-analysis. Aging Male. 2015 Dec;18(4):233–7.
  • Abrahamsson P-A. Intermittent androgen deprivation therapy in patients with prostate cancer: Connecting the dots. Asian J Urol. 2017 Oct;4(4):208–22.
  • Magnan S, Zarychanski R, Pilote L, Bernier L, Shemilt M, Vigneault E, et al. Intermittent vs Continuous Androgen Deprivation Therapy for Prostate Cancer: A Systematic Review and Meta-analysis. JAMA Oncol. 2015 Sep 17;1–10.
  • Botrel TEA, Clark O, dos Reis RB, Pompeo ACL, Ferreira U, Sadi MV, et al. Intermittent versus continuous androgen deprivation for locally advanced, recurrent or metastatic prostate cancer: a systematic review and meta-analysis. BMC Urol. 2014;14:9.

Order printed copies of this publication

Before you order we would like to know who you are, and why you are ordering printed copies.

Download digital versions of this publication